BioRad Laboratories (BIO)
(Delayed Data from NYSE)
$301.92 USD
+5.10 (1.72%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $302.11 +0.19 (0.06%) 6:24 PM ET
3-Hold of 5 3
C Value C Growth D Momentum D VGM
Bio-Rad Laboratories (BIO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$350.50 | $402.00 | $300.00 | 18.09% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Bio-Rad Laboratories comes to $350.50. The forecasts range from a low of $300.00 to a high of $402.00. The average price target represents an increase of 18.09% from the last closing price of $296.82.
Analyst Price Targets (4 )
Broker Rating
Bio-Rad Laboratories currently has an average brokerage recommendation (ABR) of 2.25 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 2.25 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, one is Strong Buy and one is Buy. Strong Buy and Buy each account for 25% of all recommendations. A month ago, Strong Buy made up 25%, while Buy represented 25%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 2 | 2 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 2 | 2 | 2 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.25 | 2.25 | 2.25 | 1.75 | 1.75 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/3/2024 | Not Identified | Not Identified | Not Available | Hold |
5/8/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
5/8/2024 | UBS | Dan Leonard | Strong Buy | Strong Buy |
4/3/2024 | Not Identified | Not Identified | Strong Buy | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.25 |
ABR (Last week) | 2.25 |
# of Recs in ABR | 4 |
Average Target Price | $350.50 |
LT Growth Rate | NA |
Industry | Medical - Products |
Industry Rank by ABR | 76 of 252 |
Current Quarter EPS Est: | 2.12 |